These studies consistently report decreased expression of PHLDA3 in cancers such as neuroendocrine tumors (NETs) [5,12], squamous cell carcinoma (SCC) [10,13], esophageal SCC (ESCC) [13], and prostate cancer [4]. This evidence concerns the gene PHLDA3 and prostate cancer.